Santhera Pharmaceuticals Holding AG (OTCPK:SPHDF) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Santhera Pharmaceuticals Holding AG had a gross margin of 43.79% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Santhera Pharmaceuticals Holding AG Gross Margin % Related Terms
Santhera Pharmaceuticals Holding AG Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Santhera Pharmaceuticals Holding AG Gross Margin % Chart
SPHDF vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, Santhera Pharmaceuticals Holding AG's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Santhera Pharmaceuticals Holding AG Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Santhera Pharmaceuticals Holding AG's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Santhera Pharmaceuticals Holding AG's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Santhera Pharmaceuticals Holding AG (SPHDF) has a Gross Margin % of 43.79% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Santhera Pharmaceuticals Holding AG and its competitors. This is 46% below median its historical median of 80.86. Over the past decade, Santhera Pharmaceuticals Holding AG's Gross Margin % has ranged from 19.66 to 336.18. According to the industry distribution chart, Santhera Pharmaceuticals Holding AG ranks #618 out of 738 companies in the Biotechnology industry, placing it in the top 83.7%.
Is Santhera Pharmaceuticals Holding AG's Gross Margin % too high?
Santhera Pharmaceuticals Holding AG's current Gross Margin % of 43.79% is 46% below median its 10-year median of 80.86. Over the past 10 years, this metric has ranged from a low of 19.66 to a high of 336.18. The Biotechnology industry median Gross Margin % is 60.94. Santhera Pharmaceuticals Holding AG's value of 43.79% is 28.1% below this industry median. Based on the distribution chart, Santhera Pharmaceuticals Holding AG ranks #618 out of 738 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Santhera Pharmaceuticals Holding AG has a GF Scoreâ„¢ of 39/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Santhera Pharmaceuticals Holding AG's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Santhera Pharmaceuticals Holding AG ranks #618 out of 738 companies for Gross Margin %. This places Santhera Pharmaceuticals Holding AG in the lower half of its industry. The industry median Gross Margin % is 60.94. Santhera Pharmaceuticals Holding AG's value of 43.79% is 28.1% below this benchmark. Historically, Santhera Pharmaceuticals Holding AG's own Gross Margin % has ranged from 19.66 to 336.18 over the past decade. While the company's 10-year median is 80.86 vs. the industry median of 60.94, Santhera Pharmaceuticals Holding AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.94, based on 738 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Santhera Pharmaceuticals Holding AG's current Gross Margin % of 43.79% is 28.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Santhera Pharmaceuticals Holding AG and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Santhera Pharmaceuticals Holding AG's current Gross Margin % is 43.79%, which is 46% below median its own 10-year median of 80.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Santhera Pharmaceuticals Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Santhera Pharmaceuticals Holding AG (SPHDF) is currently considered Fairly Valued. The stock's GF Value™ is $24.73, compared to a current price of $23.25 — trading 6% below its estimated fair value. The current Gross Margin % is 43.79%, which is 46% below median its 10-year median of 80.86 and 28.1% below the Biotechnology industry median of 60.94. Santhera Pharmaceuticals Holding AG's overall GF Score™ is 39/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Santhera Pharmaceuticals Holding AG (SPHDF), the current Gross Margin % is 43.79% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Santhera Pharmaceuticals Holding AG (SPHDF) Overvalued in 2026?
Based on GuruFocus' analysis, Santhera Pharmaceuticals Holding AG stock appears to be undervalued.
The current stock price of $23.25 is trading 6% below its estimated GF Value™ of $24.73.
GuruFocus considers Santhera Pharmaceuticals Holding AG to be Fairly Valued.
Key valuation signals for SPHDF:
Gross Margin %: 43.79% (46% below median its 10-year median of 80.86)
GF Value™: $24.73 vs. price of $23.25 (6% below fair value)
Industry Position: 28.1% below the Biotechnology median (#618 of 738)
No single metric tells the full story. See the SPHDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Santhera Pharmaceuticals Holding AG Business Description
Santhera Pharmaceuticals Holding AG is a Swiss specialty pharmaceutical company committed to developing and commercializing medicines to meet the needs of patients living with rare and other diseases with high unmet medical needs. It is focused on the development of treatments for pulmonary and neuromuscular diseases that currently lack treatment options. The company is currently engaged in the rollout of its AGAMREE (vamorolone) medicine for the treatment of Duchenne muscular dystrophy (DMD) globally. Santhera has one operating segment, namely the development and commercialization of products for the treatment of neuromuscular diseases. Geographically, the company generates maximum revenue from Europe, and the rest from Asia and North America.
39GF Score
Get the complete analysis for SPHDF
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SPHDF has been successfully added to your 
